Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 50:1551-1560, doi:10.1016/j.jacc.2007.07.019 (Published online 1 October 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Cardiosource Slide Set
Right arrow View Online Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (28)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Givertz, M. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Givertz, M. M.

The Effects of KW-3902, an Adenosine A1-Receptor Antagonist,on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance

Michael M. Givertz, MD, FACC*,1,*, Barry M. Massie, MD, FACC{dagger},2, Tara K. Fields, BA{ddagger},3, Leeanne L. Pearson, RN, BS{ddagger},3, Howard C. Dittrich, MD, FACC{ddagger},§,3 on behalf of the CKI-201 and CKI-202 Investigators

* Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
{dagger} Cardiology Division, San Francisco Veterans Affairs Medical Center, San Francisco, California
{ddagger} NovaCardia, Inc., San Diego, California
§ University of California, San Diego, California.


Figure 1
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Flow Diagrams Depicting Study Protocols

(A) Acute decompensated heart failure (ADHF) patients with renal impairment. (B) ADHF patients who were resistant or refractory to diuretics. CrCl = creatinine clearance; IV = intravenous.

 

Figure 2
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Urine Output in First 6 h

Cumulative urine volume (mean ± SEM) 6 h after initiation of placebo or KW-3902 in acute decompensated heart failure patients with renal impairment (*p = 0.02 vs. placebo).

 

Figure 3
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Daily Administration of IV Diuretics

Daily dose of intravenous (IV) furosemide (mean ± SEM) administered to the placebo and 4 KW-3902 groups over the first 3 days of the study (*p < 0.05 vs. placebo).

 

Figure 4
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 Change in Urine Output over 24 h

Change in hourly urine volume (mean ± SEM) through 24 h after dosing with placebo or KW-3902 in acute decompensated heart failure patients refractory/resistant to diuretics.

 

Figure 5
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 5 Change in Urine Flow Rate at 6 h

Change in urine flow rate (mean ± SEM) between 5 h and 6 h after administration of placebo or KW-3902 compared with baseline.

 

Figure 6
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 6 Change in CrCl over 24 h

Change in measured creatinine clearance (CrCl) (mean ± SEM) relative to baseline in acute decompensated heart failure patients refractory/resistant to diuretics (*p < 0.05 vs. baseline).

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement